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ABSTRACT 
Small Cell Carcinoma of the bladder accounts for less than 1% of all bladder tumors. Small Cell Carcinoma of the 
bladder has an aggressive behaviour and is usually metastatic at diagnosis. Due to its infrequent occurence, the 
literature on this entity is limited; which unsurprisingly leads to an uncertanity in defining an ideal therapeutic approach. 
This report, overviews the literature while describing a 70- year- old female patient who is diagnosed with  small cell 
carcinoma of the bladder arising in an unusual localization. 
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ÖZET 
Mesanenin küçük hücreli karsinomu, tüm mesane tümörleri içinde 1% den az sıklıkta izlenir. Agresif davranışından 
dolayı tanı konulduğunda sıklıkla metastaz yapmıştır. Nadir görülmesi nedeniyle az sayıda literatür bilgisi vardır. Bu 
durum ideal tedavide belirsizliğe neden olmaktadır. Bu olguda mesane tavanında yerleşim gösteren, mesanenin küçük 
hücreli karsinomu tanısı alan 70 yaşındaki kadın hasta literatür eşliğinde sunuldu. 
Anahtar kelimeler: Mesane karsinomu, kemoterapi, küçük hücreli karsinom. 
INTRODUCTION 
 Small Cell Carcinoma of the bladder (SCCb) is 
a neuroendocrine tumor. Small cell carcinomas 
usually arise in the lungs, salivary glands, larynx, 
oesophagus, stomach, colon, rectum and skin.  
The most common sites of involvement along the 
urinary tract are the urinary bladder, prostate and 
kidneys
1
. Involvement of urethra, testicles, ureters 
and adrenal glands is less common. 
 Here we report a case of SCCb, a rare non-
urothelial tumor associated with a poor prognosis, 
arising in an unusual localization. 
CASE REPORT 
 A 70–year-old female patient presented with 
gross haematuria and clots in the urine. The 
physical examination of the patient, who had a 35-
year smoking history, was unremarkable. Following 
the urinalysis that confirmed hemoglobinuria, the 
patient was evaluated by urinary tract 
ultrasonography (USG). USG revealed a 50x40 
mm mass in the bladder, prompting a contrast 
enhanced CT scan (Figure 1). The axial contrast 
enhanced CT imaging revealed prominent 
thickening and contrast enhancement of the 
anterior wall of the bladder. A transurethral 
cystoscopy confirmed a 50-mm solid mass 
originating from the bladder dome through the 
anterior wall. 
 The patient underwent transurethral resection 
of the bladder tumor (TUR BT, April 2013). During 
the operation it was noted that the tumor invaded 
muscularis propria and there was an 
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intraabdominal fluid collection. Due to suspected 
bladder perforation a decision was made to 
convert the operation to an open surgical 
operation. The urinary bladder was accessed via a 
midline suprapubic incision and a 1x1 cm 
perforated area was noted on the bladder dome. 
Thus, a wide partial cystectomy was performed 
around the perforation site. Following the closure 
of bladder wall, the peritoneum was accessed and 
the fluid collection was aspirated. After placing a 
perivesical drain, the surgery was terminated. The 
patient’s postoperative course was uneventful and 
she was discharged with a urethral catheter on the 
postoperative third day.  
 The histopathologic evaluation of the resected 
specimen revealed a small cell carcinoma invading 
the bladder wall thoroughly and infiltrating the 
perivesical adipose tissue as well. In situ 
carcinoma was detected in the peritumoral bladder 
mucosa. Immunohistochemical analysis for further 
characterization of the tumor tissue revealed that 
the malignant cells were stained diffusely with 
Synaptophysin and Thyroid Transcription Factor-1 
(TTF1) and focal expression of Epithelial 
Membrane Antigen (EMA), pancytokeratin 
(PanCK) and Chromogranin. No staining with p63, 
CD56, PGP 9.5, or 34BE12 was detected in 
malignant cells. Hence, the tumor was diagnosed 
as SCC of the bladder (Figure 2). Abdominal and 
thoracic computed tomography (CT) scans 
performed for staging demonstrated no clinically 
relevant pathologic findings. The tumor stage was 
determined T2 (TNM staging system) and the 
patient was offered various treatment modalities 
including radical cystectomy. However she refused 
any surgical treatment or further examination, so 
was referred to medical oncology for 
chemotherapeutic intervention. She received 4 
cycles of Cisplatin plus Etoposide   based 
chemotherapy. Futher surgical treatment was 
suggested again but the patient did not accept. So, 
pelvic radiotherapy (180Gy in 28 fractions and 
200Gy in 5 fractions) was administered. After a 
year of follow up the patients is still alive. 
 
 
                                 Figure 1. Axial contrast enhanced CT imaging shows prominent thickening  
                                 and contrast enhancement of the anterior wall of the bladder (white arrow). 
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                                               Figure 2. Small cell carcinoma of the bladder. Sheets and aggregates 
                                               of loosely cohesive cells with hyperchromatic small nuclei and scant 
                                               cytoplasm (HEx40). 
 
DISSCUSSION 
 SCCb accounts for less than 1% of all bladder 
tumors
2
. As the rest of the bladder carcinomas, the 
most common symptom at presentation is 
hematuria. Half of the affected patients have a 
smoking history
2
. SCC of the bladder commonly 
occurs (15.7%) in the lateral walls of the bladder, 
but can rarely (2%) arise in the dome, as in our 
patient
3
.  
 The etiopathogenesis of SCCb is not yet clear. 
However, the malignant transformation of 
pluripotent stem cell-derived cells is one of the 
most credited theories
4
.
 
 SCCb shares similar histological 
characteristics with its counterpart arising in lung. 
Therefore, the differential diagnosis should include 
metastasis of small cell carcinoma of lung, along 
with other malignancies such as the bladder 
invasion of prostatic small cell carcinoma (SCCp) 
and lymphoma. Differential diagnosis of SCCp and  
 
 
 
 
 
 
lymphoma requires performance of detailed 
histopathological and immunohistochemical 
methods. Both SCCp and SCCb express 
neuroendocrine markers, while Prostate-Spesific 
Antigen (PSA) and prostatic acid phosphatase 
(PSAP) are expressed only by SCCp
5
.
 
Lymphomas 
express Leucocyte Common Antigen (LCA) and 
are negative for neuroendocrine markers or 
Cytokeratin
6
.
  
SCCb mainly (61.4%) occurs in pure 
form, but concomitant areas of adenocarcinoma 
and transitional cell carcinoma are not uncommon 
(38.6%)
7
. Fifty-two percent of SCCb is metastatic at 
diagnosis
8
. The common sites of metastasis of this 
highly aggressive tumor are pelvic and extrapelvic 
lymph nodes, lungs, liver, mediastinum, adrenal 
glands, bowels, and brain
8
. The ultimate diagnosis 
is based on the histopathologic evaluation of the 
resected tissues. Two staging systems can be 
used to evaluate the extent of the disease; the 
TNM staging system is used by urologists in most 
studies while the clinical stage also implies if the 
disease is localized or extensive. 
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 Contrast enhanced CT scans including 
abdomen, thorax, cranium and pelvis should be 
preferred for the evaluation of disease stage. 
Owing to its high sensitivity, magnetic resonance 
imaging can be the first choice in detecting the 
extravesical and adjacent organ involvement in 
patients who are planned to undergo radical 
surgery. Although multimodal combined therapies 
such as radical surgery, radiotherapy, and 
chemotherapy are suggested for management of 
these patients, no consensus has been reached 
yet
7
.   
 A Mayo Clinic series consisting of 44 patients 
showed that radical cystectomy alone could not 
achieve cure. Furthermore, there are no studies 
reporting advantages or disadvantages of 
cystectomy or radiotherapy over chemotherapy 
alone9. The aggressive behavior and unfavorable 
progression of the tumor could cause relapses. 
Radical surgery, partial cystectomy and TUR-
bladder tumor procedures are not efficient even in 
regional disease4. Recent studies have shown that 
neoadjuvant chemotherapy (four cycle Etoposide  
plus Cisplatin or doxorubicin plus ifosfamide) 
performed in surgically resectable SCCb patients 
achieves downstaging of the tumor and prolongs 
survival10. The authors detected a disease-
specific survival of 5 years in 79% of patients 
undergoing radical cystectomy following 
chemotherapy10. Thus, we offered the patient a 
combined therapy consisting of radical surgery and 
chemotherapy (neoadjuvant and adjuvant). 
However, she refused surgical treatment and was 
referred to medical oncology for chemotherapy. 
She received Cisplatin plus Etoposide based 
chemotherapy. Futher surgical treatment was 
suggested again but the patient did not accept. 
 In conclusion, SCC of the bladder is a rare 
tumor with a poor prognosis. It may develop in 
unusual localizations. There is no well-established 
treatment strategy for management of these 
patients. The patient should be informed 
thoroughly about the treatment options. This 
disease requires a multidisciplinary treatment 
approach. 
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